Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Brenner Tumor 2Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 24Carboplatin 21Taxes 15Bevacizumab 9Cisplatin 7Immunoglobulin G 6Disulfides 6Topotecan 3Docetaxel 3paclitaxel poliglumex 2VTX-2337 2SS1(dsFv)PE38 2Platinum 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Filgrastim 2Etoposide 2Erlotinib Hydrochloride 2Chemotherapy, Adjuvant 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1liposomal doxorubicin 1emactuzumab 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brenner Tumor × VTX-2337 × Gynecologic × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

NCT01294293 2014-12-25

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

GOG Foundation

Phase 1 Completed
20 enrolled
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡